Scrip Roundtable Debate
Adopting Orphans - A Call to Arms for Collaboration Part 1: Scoping the orphan disease landscape
Once eschewed by big pharma, increasing numbers of companies are entering the rare diseases arena, both through acquisitions and partnerships with smaller players. Why the interest in orphan drugs, and why now?
Watch the latest Scrip Roundtable debate Part 1 to 6 to understand the opportunities and challenges for the pharmaceutical industry as it seeks to create value and deliver novel medicines to patients in the orphan drugs space.